2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2206 Dynamics of renal recovery and regimen-specific outcomes in multiple Myeloma–Associated kidney disease

Miranda De la Luz Franco, MD, Martha Paola Anchondo Commesse, MD2, Andrea Victoria Pacheco, MD3, Diego Jose Fuentes Cañas, MD4, Jay R Hydren, PhD5, Samuel Bennion6, Jennifer M Ahlstrom, BA7, Karla Mariana Castro Bórquez, MD8, Edgar Ricardo Olivas Domínguez, MD9, Magaly Valeria Escobedo Cruz10, Jorge Arturo Hurtado Martinez, MD, MHSc11
1 HealthTree Foundation, South Jordan, Utah, United States
2 HealthTree Foundation, South Jordan, Utah, United States
3 HealthTree Foundation, South Jordan, Utah, United States
4 HealthTree Foundation, South Jordan, Utah, United States
5 HealthTree Foundation, South Jordan, Utah, United States
6 HealthTree Foundation, South Jordan, Utah, United States
7 HealthTree Foundation, South Jordan, Utah, United States
8 HealthTree Foundation, South Jordan, Utah, United States
9 HealthTree Foundation, South Jordan, Utah, United States
10 HealthTree Foundation, South Jordan, Utah, United States
11 HealthTree Foundation, South Jordan, Utah, United States
Background 

Renal impairment is a common complication of multiple myeloma and remains a major therapeutic challenge. Although reversing this impairment is a key therapeutic goal, how renal function recovers after first-line therapy in clinical practice has not been thoroughly described. In this study, we evaluated the timing, depth, durability, and regimen-specific characteristics of renal recovery in a real-world cohort.

Methods 

We screened 2,296 myeloma patients from the HealthTree registry with at least one documented line of therapy, and identified 202 patients with laboratory evidence of renal dysfunction and/or a documented diagnosis of renal impairment. Data were extracted on June 22, 2026. Individual medical records and clinical notes were manually reviewed to determine whether kidney disease was attributable to multiple myeloma. Among 166 patients evaluated for kidney conditions, 125 had myeloma-attributable kidney disease. Of these, we included 111 patients who had documented laboratory results to evaluate renal response during first-line therapy in our final analytic cohort. For the assessment of renal function, we used CKD-EPI 2021. We defined baseline renal function as the measurement closest to the start of  first-line therapy (within a -30 to +21-day window) and best response as the first measurement achieving the deepest response category. Renal response was classified according to International Myeloma Working Group (IMWG) criteria. We defined renal relapse as 2 consecutive measurements showing a >25% decline from the best recorded estimated glomerular filtration rate (eGFR) and recovery as any subsequent sustained renal response. Involved free light chain clearance was defined as a ≥90% reduction from baseline. Finally, first-line regimens were grouped by combination class and number of agents. For comparisons, we used Fisher's exact and Mann–Whitney U tests, and for time-to-response analyses, we used Kaplan–Meier estimates and log-rank tests.

Results 

Among the 111 patients with multiple myeloma–associated kidney disease, the baseline mean eGFR was 40.5 mL/min/1.73 m² (95% CI 34.9–46.1, n=99). At 6 months, the mean eGFR improved to 65.1 mL/min/1.73 m² (95% CI 58.5–71.7, n=84) and remained stable at 63.6 mL/min/1.73 m² (95% CI 57.6–69.6, n=83, p<0.05) at 12 months. Of the total cohort, 75 patients were evaluable for IMWG renal response (baseline eGFR <60). A sustained response was achieved by 64 of these patients (85.3%) after first-line therapy at a median of 32 days (IQR 27–97.8). Among these 64 responding patients, kidney recovery was rapid and predominantly complete. Most patients (53, 82.8%) achieved a complete renal response (CRrenal), and 44 (68.8%) achieved their best renal response at the time of their initial response. Half of the responding patients experienced a renal relapse  (n=32). These relapses, however, were largely transient; 30 patients (93.8%) subsequently achieved renal recovery after a median of 21 days (IQR 6.2–42.2), and  22 of them fully regained their previous depth of renal response. 

Among the different first-line regimens, quadruplet therapy (anti-CD38 + PI + IMiD + corticosteroids) achieved the highest overall renal response rate (93.9%) and complete renal response rate (81.8%). This intensive regimen also led to the fastest recovery, with a median time to renal response of 28 days. In contrast, patients receiving PI + alkylator + corticosteroids regimens recovered much more slowly, taking a median of 52 days to respond.

Conclusions 

In this real-world cohort of patients with multiple myeloma–associated kidney disease, renal recovery was characterized by rapid achievement of maximal response rather than gradual improvement, with nearly 70% of responders achieving their deepest renal response at the time of first response. Although renal relapses were common after an initial response, they were typically transient, and most patients regained their previous depth of renal response. Among the evaluated first-line regimens, quadruplet therapy showed the highest renal response rates and the shortest median time to renal recovery. These findings clarify the dynamics of renal recovery in multiple myeloma and support further prospective evaluation of regimen-specific differences in renal outcomes.

Miranda De la Luz Franco, MD: No relevant conflicts of interest to declare.